The Impact of Polymer Size and Cleavability on the Intravenous Pharmacokinetics of PEG-Based Hyperbranched Polymers in Rats.
biodistribution
hyperbranched polymer
nanomaterials
nanomedicine
nanoparticles
pharmacokinetics
poly (ethylene glycol)
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
08 Dec 2020
08 Dec 2020
Historique:
received:
16
11
2020
revised:
02
12
2020
accepted:
03
12
2020
entrez:
11
12
2020
pubmed:
12
12
2020
medline:
12
12
2020
Statut:
epublish
Résumé
A better understanding of the impact of molecular size and linkers is important for PEG-based hyperbranched polymers (HBPs) intended as tailored drug delivery vehicles. This study aimed to evaluate the effects of crosslinker chemistry (cleavable disulphide versus non-cleavable ethylene glycol methacrylate (EGDMA) linkers) and molecular weight within the expected size range for efficient renal elimination (22 vs. 48 kDa) on the intravenous pharmacokinetic and biodistribution properties of
Identifiants
pubmed: 33302413
pii: nano10122452
doi: 10.3390/nano10122452
pmc: PMC7762536
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : The University of Queensland, internal support fund
ID : .
Références
Mol Pharm. 2017 Dec 4;14(12):4485-4497
pubmed: 29116801
Biomacromolecules. 2011 Oct 10;12(10):3478-86
pubmed: 21894897
Expert Opin Drug Deliv. 2016 Sep;13(9):1257-75
pubmed: 27116988
Mol Pharm. 2011 Apr 4;8(2):338-49
pubmed: 21171585
Nanomedicine (Lond). 2016 Dec;11(24):3223-3235
pubmed: 27830630
Mol Pharm. 2006 Sep-Oct;3(5):614-27
pubmed: 17009860
Eur J Pharm Sci. 2019 Feb 1;128:73-80
pubmed: 30465818
Mol Pharm. 2009 Jul-Aug;6(4):1190-204
pubmed: 19453158
Biomaterials. 2017 Oct;141:330-339
pubmed: 28711780
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51
pubmed: 26456916
J Pharm Sci. 2009 Oct;98(10):3871-5
pubmed: 19283758
Drug Deliv Transl Res. 2013 Jun 1;3(3):260-271
pubmed: 23795337
Expert Opin Drug Deliv. 2017 Jan;14(1):1-5
pubmed: 27852113
J Control Release. 2019 Aug 10;307:32-43
pubmed: 31152749
Drug Deliv Transl Res. 2019 Jun;9(3):721-734
pubmed: 30895453
Sci Rep. 2019 Oct 29;9(1):15465
pubmed: 31664080
Mol Pharm. 2008 Jul-Aug;5(4):505-15
pubmed: 18672949
Nanomaterials (Basel). 2020 Apr 20;10(4):
pubmed: 32325941
Nanomedicine (Lond). 2017 Apr;12(8):819-823
pubmed: 28338401
ACS Nano. 2015 Sep 22;9(9):9217-27
pubmed: 26301576
Oncol Lett. 2016 Dec;12(6):5332-5334
pubmed: 28105242
Mol Pharm. 2008 May-Jun;5(3):449-63
pubmed: 18393438
Mol Pharm. 2015 Feb 2;12(2):432-43
pubmed: 25485615
Mol Pharm. 2012 Mar 5;9(3):422-32
pubmed: 22233281
Biomacromolecules. 2020 Aug 10;21(8):3318-3331
pubmed: 32687312
J Med Chem. 2015 May 14;58(9):4066-72
pubmed: 25860834
Nanomedicine (Lond). 2011 Aug;6(6):1063-84
pubmed: 21955077
Drug Deliv Transl Res. 2020 Jun;10(3):721-725
pubmed: 32166632
Eur J Pharm Biopharm. 2018 Apr;125:1-12
pubmed: 29309835
Chem Commun (Camb). 2018 Oct 11;54(82):11538-11541
pubmed: 30182121
Nanomedicine. 2017 Nov;13(8):2485-2494
pubmed: 28821463
J Pharm Sci. 2016 Jan;105(1):293-300
pubmed: 26852861
Mol Pharm. 2017 Oct 2;14(10):3539-3549
pubmed: 28880092
Nucl Med Biol. 2011 Jul;38(5):675-81
pubmed: 21718943
Int J Pharm. 2020 Feb 25;576:118959
pubmed: 31870963
Methods Mol Biol. 2018;1762:271-284
pubmed: 29594777
Eur J Pharm Biopharm. 2019 Apr;137:218-226
pubmed: 30851352
Nanomedicine. 2016 May;12(4):893-900
pubmed: 26772431
Eur J Pharm Sci. 2014 Dec 18;65:147-55
pubmed: 25261338
J Am Chem Soc. 2012 Feb 1;134(4):2139-47
pubmed: 22191645
Nanotechnology. 2009 Apr 22;20(16):165101
pubmed: 19420561
Front Pharmacol. 2018 Jul 17;9:790
pubmed: 30065653
Bioconjug Chem. 2017 Sep 20;28(9):2211-2223
pubmed: 28767228